Novel systems for alginate-immobilized mammalian cell culture in bioreactors

BIOT 458

Corinne A Hoesli, choesli@chml.ubc.ca1, Kamini Raghuram, kammyrag@hotmail.com1, Minh Luu, luu.minh@gene.com2, Jill Osborne3, Gregory Korbutt, korbutt@ualberta.ca4, and James M. Piret, jpiret@chml.ubc.ca1. (1) Michael Smith Laboratories & Department of Chemical and Biological Engineering, University of British Columbia, 251 - 2185 East Mall, Vancouver, BC V6T 1Z4, Canada, (2) Process Development (LSCC), Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, (3) Department of Chemical Engineering and Applied Chemistry, University of Toronto, (4) Department of Surgery, University of Alberta, 1074 Dentistry/Pharmacy Centre, Edmonton, AB T6G 2N8, Canada
Immobilization in 3D matrices is increasingly used for stem cell differentiation and tissue engineering applications, including for the generation of islets for diabetes therapy. Two novel processes for alginate-immobilized mammalian cell culture are being developed to make clinical and larger scale implementation more practical: an alginate-filled hollow fiber bioreactor (AHFBR) and alginate beads formed by emulsion/internal gelling. The cell lines chosen for proof-of-concept experiments formed discrete pancreatic islet-sized aggregates in alginate. The AHFBR allowed 25-fold expansion of CHO cells in 8 days and 10-fold expansion of Min6 cells was achieved in 11 days in the emulsion beads. Using primary human pancreatic cells, ~ 50% live cell recovery was obtained immediately after the emulsion bead process. The losses observed were mainly attributed to the acidic condition required for bead gelling. No significant detriments to scale-up were found after 10 days of culture of primary neonatal porcine pancreatic cells in the AHFBR.
 

Upstream Processing: Advances in Tissue Engineering
8:00 AM-11:00 AM, Thursday, August 23, 2007 BCEC -- 107C, Oral

Division of Biochemical Technology

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007